Numerous studies have found that certain PD‐L1‐negative patients can also benefit from anti‐PD‐L1 and anti‐PD‐1 therapy, likely due to a combination of factors such as the heterogeneity of PD‐L1 expression, variations in detection methods, glycosylation modifications of the PD‐L1 molecule, and the dynamic changes in the tumor immune microenvironment [6]. Here, CD274 is linked to neoplasm.